“On aver­age, the med­ica­tions pre­scribed for brain-relat­ed con­di­tions ben­e­fit approx­i­mate­ly 50% of patients. But which 50%?.” “We need unam­bigu­ous bio­mark­ers that are clin­i­cal­ly rel­e­vant and scal­able at rea­son­able cost. They already exist in Can­cer. But they do not yet exist in the Brain.” What may change that? We are hon­ored to bring to Sharp­Brains read­ers a new…